Suneel L. Mahajan
Career history of Suneel L. Mahajan
Former positions of Suneel L. Mahajan
| Companies | Position | Start | End |
|---|---|---|---|
Multivir, Inc.
 Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Director/Board Member | 01/02/2015 | - |
| Independent Dir/Board Member | 01/02/2015 | - |
Training of Suneel L. Mahajan
| B.J. Govt. Medical College & Sassoon General Hospitals | Doctorate Degree |
Statistics
International
| United States | 2 |
| India | 2 |
Operational
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Multivir, Inc.
Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Health Technology |
- Stock Market
- Insiders
- Suneel L. Mahajan
- Experience
